48 results about "Antiinfective agent" patented technology

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

The invention provides semi-solid or liquid pharmaceutical compositions for topical administration to a finger- or toenail of a human. The compositions are useful for the delivery of active ingredients deep into the nail. Various active ingredients may be incorporated, such as antifungal agents, anti-infectives, anti-inflammatory agents, immunosuppressants, local anesthetics, and retinoids.

The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

The invention provides compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A1, A8, R2, R3, R5, R6, R7, and R9 are defined herein.Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of compounds of Formula I and / or Formula II and one or more other active agents. The invention also provides methods for treating microbial and protozoal infections in animals.

Sixteen membered macrolide anti-infective agents having a structure according to formula I where R1, R2, R3, R4, R5, and R6 are as defined herein, and related compounds are disclosed.

In one aspect of the invention, the antiinfective agents are flavonol compounds of the represented by formula I:Another aspect of the invention is a method for treating an infection in a subject by administering the compounds of Formula I to the subject.

The present invention provides methods for the treatment or prevention of a viral, bacterial, or fungal infection using an anionic cellulose- or acrylic-based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose based polymer or acrylic based polymer or prodrug of either. The present invention also provides pharmaceutical compositions comprising an anionic cellulose or acrylic based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose-based polymer or prodrug. The present invention further provides combination therapies for the treatment or prevention of a viral, bacterial, or fungal infection using an anionic cellulose or acrylic-based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose based or acrylic based polymer or prodrug of either and one or more anti-infective agents.

The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles, aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and / or anti-infective / antibiotic / anti-fungal agents, accepted as safe and efficacious for ophthalmic use.